EPS for AnaptysBio, Inc. (ANAB) Expected At $-0.71

July 13, 2018 - By Nellie Rakes

Analysts expect AnaptysBio, Inc. (NASDAQ:ANAB) to report $-0.71 EPS on August, 9.They anticipate $0.58 EPS change or 446.15 % from last quarter’s $-0.13 EPS. After having $-0.63 EPS previously, AnaptysBio, Inc.’s analysts see 12.70 % EPS growth. The stock decreased 3.79% or $2.82 during the last trading session, reaching $71.51. About 213,406 shares traded. AnaptysBio, Inc. (NASDAQ:ANAB) has risen 191.76% since July 14, 2017 and is uptrending. It has outperformed by 179.19% the S&P500.

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company has market cap of $1.68 billion. The company??s proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It currently has negative earnings. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize an anti-PD-1 antagonist antibody and an anti-TIM-3 antagonist antibody (TSR-022), which are under clinical development; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 checkpoint agonist antibody (CC-90006) that is in clinical stage.

AnaptysBio, Inc. (NASDAQ:ANAB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.